Topics

Articles

PC's new editor-in-chief details his thought process on familiarizing himself with a different side of the industry

Diving in Headfirst

It's time to include hubs in the patient treatment journey

Shedding the Secondary Label

Guy Levy-Yurista, PhD, is CEO of Synthace.

The connection between what we can do online and a physical location has long been broken. The same transformative upheaval is coming in life sciences—and it will be CDMOs that lead the way, writes Guy Levy-Yurista

How CDMOs Will Lead the Way Towards True Cloud Lab Enablement

Michael Wong is an Emeritus Board Member of the Harvard Business School Healthcare Alumni Association.

Harvard Business School Professor Amy C. Edmondson talks about achieving psychological safety in the workplace.

The Role of Fearless Organizations in Global Crises

From supply-chain and clinical-trial disruptions in Ukraine and Russia, to decisions to halt investment or maintain operations, global implications for industry and pharmaceutical production are immense.

Ukraine Invasion Challenges Biopharma Research and Operations

Scott Howell is Chief Strategy Officer, US Pharmaceuticals, at Novartis.

Ray Pressburger is Managing Director, Life Sciences Strategy at Accenture. 

The life sciences industry is at an inflection point, with pressures around pricing, patient access, and affordability converging with the cost of increasingly complex and personalized medicines to make today’s economics unsustainable. Scott Howell and Ray Pressburger discuss what can be done to help solve these challenges across the industry.

An Economic Path Forward: Thoughts on an Industry Inflection Point

 Introducing our first deep dive into pharma's indispensable partner—the 3PL

The Lowdown on Logistics

Can technology really build trust in pharmaceutical supply chains?

Striving for Authentic, Transparent Track and Trace

A prescription for making the pharma supply chain more resilient, reliable and disruption-proof

Right product, right place, right away

The promise of advanced AI in transforming the value picture in drug development

Opinion